Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.

Oxygen, Inc. wholesales and markets oxygen. The company was founded on June 24, 2002 and is headquartered in Elizabeth, CO.

Angiogene Pharmaceuticals Ltd., a drug discovery company, engages in developing drug candidates for the treatment of cancer and other angiogenic diseases. It develops compounds to the preclinical stage and at that point licenses to pharmaceutical and drug development companies. The company also carries out research activities on contract basis. Its product pipeline includes ZD6126, a vascular disrupting agent that acts via tubulin depolymerization; MN029, a tubulin-binding vascular disrupting agent; ANG500, a series of compounds with activity against tumour models; and ANG700, a series of hypoxia activated prodrugs. Angiogene Pharmaceuticals Ltd.

Besides Italy, where Menarini is one of the leading pharmaceutical groups, sales are mainly concentrated in Europe: Austria, Benelux, France, Germany, United Kingdom, Greece, Ireland, Portugal, Spain, Turkey and Switzerland. Menarini has now reached important positions in Eastern and Central Europe where it ranks no. 6 in the total market of this region including: Russia, Poland, Ukraine, the Baltic States, Czech Rep., Romania, Kazakhstan, Bulgaria, Belarus, Hungary, Slovak Rep., Uzbekistan, the Caucasian countries, Albania, Moldova and ex-Yugoslavia. Menarini is the leader on the market in the Baltic States, Ukraine, Belarus and ranking no. 2 in Russia and Kazakhstan.

Novartis Pharma GmbH engages in the production and sale of pharmaceutical products. The firm establishes and operates institutes for the development of medicinal products. It also conducts research and development in the field of pharmacy. The company was founded by Johann Rudolf Geigy-Gemuseus in 1758 and is headquartered in Vienna, Austria.

Kelingyuan Biotechnology (Shenzhen) Co., Ltd., established on 2021-06-02, Business scope includes general business items:Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Specialty Chemicals Sales(Free of Hazardous Chemicals).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license),The licensing program is:Drug Wholesale;Drug retail;Drug import and export;Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Galderma SA develops and markets therapeutic and aesthetic solutions for dermatology. It provides medical dermatological solutions for acne, rosacea, psoriasis and other steroid-responsive dermatoses, onychomycosis, pigmentary disorders, skin cancer and medical aesthetic and corrective solutions for skin senescence. The company was founded in 1981 and is headquartered in Paris, France.

Lexicon Pharmaceuticals, Inc. (formerly Lexicon Genetic) a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. The company's drug candidates include LX1031, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX4211 that has completed Phase II clinical trials to treat type 2 diabetes; LX2931, which is in Phase II clinical trials for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX1032 that has completed Phase II clinical trials to treat the symptoms associated with carcinoid syndrome. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. The company has drug discovery alliances with Bristol-Myers Squibb Company; Genentech, Inc.; N.V. Organon; and Takeda Pharmaceutical Company Limited. It also has drug development financing collaboration with Symphony Icon; collaboration agreement with Taconic Farms, Inc.; and an alliance with Nuevolution A/S, which provides access to Nuevolution's Chemetics platform chemistry technology.

Chengdu Kelingyuan Pharmaceutical Technology Co., Ltd., established on 2015-05-07, Business scope includes medical technology research and development;Biotechnology R&D,technology transfer,technical consulting;research and development,Sales of chemical products(Free of Hazardous Chemicals),Import and export,Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.

ErgoNex Pharma GmbH is a pharmaceutical company focused on developing and commercializing products for novel and typically underserved indications. The company is headquartered in Appenzell, Switzerland

Bofu--Ipsen (Tianjin) Pharmaceutical Co., Ltd., established on 1997-04-08, Business scope includes licensed projects:pharmaceutical production;Drug Wholesale;Drug import and export;Class III medical device business;food sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Medical Research and Experimental Development;Health Consulting Services(Does not include medical services);Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Non-residential real estate leases;housing lease;Import and export;Information Consulting Service(Not including licensing information consulting services);Business Management Consulting;Financial Advisory;Supply Chain Management Services.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Endo Pharmaceuticals Solutions, Inc. develops products to treat conditions in urology and endocrinology. The company was founded in 2009 and is headquartered in Malvern, PA.

Nippon Zoki Pharmaceutical Co. Ltd. is a private company headquartered in Chuo-ku, Japan, that manufactures pharmaceutical products.